The Directory of Pharma Companies and News

American Gene Technologies

AGT has a proprietary lentiviral platform capable of broad applications including: large and orphan indications, immuno-oncology, and monogenic disorders. AGT will enter the clinic in 2017 with a Phase 1 clinical trial to evaluate AGT103 as a functional cure for HIV. Pre-IND applications for phenylketonuria (“PKU”) and hepatocellular carcinoma (“HCC”) will follow. These therapies demonstrate the breadth of AGT’s unique lentiviral platform, including such innovations as a Transient Vector™ for temporary expression and an ImmunoTox™ vector for stimulating anti-tumor immunity in immuno-oncology applications. AGT has developed extensive IP surrounding its lentiviral platform innovations. These innovations accelerate the development of a wide variety of drug candidates, provide significant opportunities for out-licensing, and offer exciting clinical opportunities. AGT is currently closing a funding round to support the initial human trial of the HIV functional cure and the preclinical development of PKU and HCC
Category: Services
Category: Services

0 results
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.